CY1120436T1 - Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου - Google Patents

Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου

Info

Publication number
CY1120436T1
CY1120436T1 CY20181100740T CY181100740T CY1120436T1 CY 1120436 T1 CY1120436 T1 CY 1120436T1 CY 20181100740 T CY20181100740 T CY 20181100740T CY 181100740 T CY181100740 T CY 181100740T CY 1120436 T1 CY1120436 T1 CY 1120436T1
Authority
CY
Cyprus
Prior art keywords
peptides
androogenic
cancer treatment
pro
lle
Prior art date
Application number
CY20181100740T
Other languages
English (en)
Inventor
Ferdinando Auricchio
Antimo Migliaccio
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1120436T1 publication Critical patent/CY1120436T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε απομονωμένα ή κεκαθαρμένα ή μερικώς κεκαθαρμένα προερχόμενα από πεπτίδια μόρια έχοντα τον παρακάτω γενικό τύπο (S1): X-[(Pro)n-His-Pro-His-Ala-Arg-lle-Lys]m-Y. Τα πεπτίδια προορίζονται για ιατρική χρήση, ιδιαίτερα ως αντικαρκινικοί παράγοντες
CY20181100740T 2007-03-16 2018-07-17 Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου CY1120436T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89542407P 2007-03-16 2007-03-16
PCT/EP2008/053127 WO2008113770A2 (en) 2007-03-16 2008-03-14 Anti-androgen peptides and uses thereof in cancer therapy

Publications (1)

Publication Number Publication Date
CY1120436T1 true CY1120436T1 (el) 2019-07-10

Family

ID=39766539

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100740T CY1120436T1 (el) 2007-03-16 2018-07-17 Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου

Country Status (15)

Country Link
US (3) US20100189776A1 (el)
EP (2) EP2139917B1 (el)
JP (4) JP5464344B2 (el)
AU (1) AU2008228274B2 (el)
CY (1) CY1120436T1 (el)
DK (1) DK2139917T3 (el)
ES (1) ES2677566T3 (el)
HR (1) HRP20181178T1 (el)
HU (1) HUE039249T2 (el)
LT (1) LT2139917T (el)
PL (1) PL2139917T3 (el)
PT (1) PT2139917T (el)
SI (1) SI2139917T1 (el)
TR (1) TR201809422T4 (el)
WO (1) WO2008113770A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
JPWO2014188775A1 (ja) * 2013-05-23 2017-02-23 国立大学法人東北大学 アンドロゲンレセプター活性依存性乳癌細胞株の作製方法、当該細胞株を用いたスクリーニング方法、ならびに乳癌患者におけるアンドロゲンレセプター活性依存性獲得の判定方法、キット及びマーカー
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
EP4157309A1 (en) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
WO2023150720A2 (en) * 2022-02-04 2023-08-10 Hofseth Biocare Asa Medicinal uses of oligopeptides in combination with an antiandrogen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808863A (pt) * 1997-04-14 2001-09-18 Univ California Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama
AU4494399A (en) * 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
EP1379550B1 (en) * 2000-12-21 2009-03-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
US7060463B2 (en) * 2001-05-08 2006-06-13 Merck & Co., Inc. DNA molecules encoding Macaca mulatta androgen receptor
WO2005017179A2 (en) * 2003-05-30 2005-02-24 New York University Antibodies that recognize and bind phosphorylated human androgen receptor and methods of using same
WO2007041497A2 (en) * 2005-09-30 2007-04-12 Cleveland Biolabs, Inc. Modulation of androgen receptor
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy

Also Published As

Publication number Publication date
JP5998161B2 (ja) 2016-09-28
HUE039249T2 (hu) 2018-12-28
WO2008113770A3 (en) 2009-02-12
AU2008228274B2 (en) 2013-04-18
EP2139917B1 (en) 2018-04-25
JP2014087363A (ja) 2014-05-15
JP6545122B2 (ja) 2019-07-17
US20180271933A1 (en) 2018-09-27
LT2139917T (lt) 2018-07-10
US20100189776A1 (en) 2010-07-29
EP3412685A1 (en) 2018-12-12
PL2139917T3 (pl) 2018-09-28
US20150202249A1 (en) 2015-07-23
TR201809422T4 (tr) 2018-07-23
JP6689430B2 (ja) 2020-04-28
US9919023B2 (en) 2018-03-20
DK2139917T3 (en) 2018-07-23
AU2008228274A1 (en) 2008-09-25
SI2139917T1 (sl) 2018-10-30
JP2019150029A (ja) 2019-09-12
JP2010521441A (ja) 2010-06-24
US11560406B2 (en) 2023-01-24
JP5464344B2 (ja) 2014-04-09
ES2677566T3 (es) 2018-08-03
EP2139917A2 (en) 2010-01-06
HRP20181178T1 (hr) 2018-12-14
WO2008113770A2 (en) 2008-09-25
PT2139917T (pt) 2018-07-18
JP2016175927A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
CY1120436T1 (el) Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1119660T1 (el) Antibakthpiakh απο toy στοματος συνθεση
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1117319T1 (el) Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA201170521A1 (ru) Новые соединения
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων